Eli Lilly's Donanemab Approved in China for Early Alzheimer's Treatment, Following Eisai and Biogen's January Approval

Dec 18, 2024, 01:56 AM

Eli Lilly's Alzheimer’s treatment, donanemab, has received approval from China's National Medical Products Administration for use in patients with early symptomatic Alzheimer's disease. This approval offers a new option for patients in China following the earlier approval of Eisai and Biogen's Leqembi in January. Donanemab has previously been authorized in the United States, Japan, and the United Kingdom, expanding its availability for those affected by the disease. The approval comes as a joint research team from South Korea and the U.S. has revealed insights into the mechanism by which tau proteins, linked to Alzheimer's, are removed from the brain.